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ABSTRACT 
BACKGROUND:  The potential combinations of antihypertensive agents are many, 
and making rational choices depends on the characteristics of each drug and on their 
complementary mechanisms of action. 
OBJECTIVE: The aim of this study was to evaluate the effectiveness of adding 
hydrochlorothiazide (HCTZ) 12.5 mg to olmesartan 20 mg or telmisartan 80 mg on blood 
pressure (BP) in patients with moderate hypertension. 
METHODS: Consecutive outpatients atthe Centro per l'Ipertensione e la Fisiopatologia 
Cardiovascolare, University of Pavia, Pavia, Italy, of both sexes aged 39 to 75 years were 
considered eligible for enrollment if they had a sitting diastolic BP (DBP) ->99 mm Hg 
and <110 mm Hg at the end of an initial 2-week washout period. Patients were random- 
ized to olmesartan 20 mg QD or telmisartan 80 mg QD according to a prospective, 
open-label, blinded end point, parallel-arm design. After 8 weeks of monotherapy, 
patients whose BP was not controlled (DBP ->90 mm Hg) received HCTZ 12.5 mg QD 
for 8 additional weeks. Clinical and ambulatory BPs were measured at the end of the 
washout period and at the end of both treatment periods. Adverse events (AEs) were 
recorded from spontaneous reports and direct inquiry from investigators. 
RESULTS:  One hundred forty-five patients, all of whom were white, were recruited 
for the study. After the initial washout period, 13 patients did not meet the inclusion 
criteria and 6 refused to continue. A total of 126 white patients (69 men, 57 women; 
mean [SD] age, 60.2 [11.6] years) were randomized to receive monotherapy. Of  these, 
35 patients (56%) in the olmesartan group and 33 (52%) in the telmisartan group had 
previously received antihypertensive therapy. At the end of monotherapy, the 52 patients 
in the olmesartan group and the 49 patients in the telmisartan treatment group who 
were still in the study and had their BP inadequately controlled by treatment had 
HCTZ 12.5 mg QD added to their treatment regimen. Both combinations induced a 
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greater ambulatory mean (SD) systolic BP (SBP) and DBP reduction than monothera- 
py (SBP: 145.3 [6.1] in the olmesartan group and 140.1 [6.4] in the telmisartan group, 
P < 0.05; DBP: 88.1 [5.1] in the olmesartan group and 84.9 [4.9] in the telmisartan group, 
P < 0.05). The mean (SD) reduction from baseline in the telmisartan/HCTZ-treated 
patients (21.5 [10.1]/14.6 [5.2] mm Hg for 24 hours, 21.8 [10.2]/14.9 [5.2] mm Hg for 
daytime, and 20.4 [10.3]/13.7 [5.9] mm Hg for nighttime; all, P < 0.001 vs baseline) 
was significantly greater than that observed in the olmesartan/HCTZ-treated patients 
(18.8 [9.8]/12.3 [4.9] mm Hg for 24 hours, 19.3 [9.8]/12.8 [4.9] mm Hg for daytime, 
and 17.4 [10.2]/10.6 [5.5] mm Hg for nighttime; all, P < 0.001 vs baseline), with a 
significant difference between the 2 treatment groups (P < 0.01). Compared with mono- 
therapy, the add-on effect of HCTZ 12.5 mg QD administration was significantly 
greater in the telmisartan group than in the olmesartan group (P < 0.05); the differ- 
ence being more evident for nighttime BP values (SBP, P 0.031; DBP, P 0.025). 
Reported AEs were similar in the olmesartan/HCTZ and the telmisartan/HCTZ groups 
(4 patients [7%] vs 3 patients [6%]). 
CONCLUSION:  The addition of HCTZ 12.5 mg to telmisartan 80 mg monothera- 
py was associated with greater BP reduction than the addition of the same dose of 
HCTZ to olmesartan 20 nag monotherapy in these patients previously uncontrolled on 
monotherapy. (Cuff Ther Res C/in Exp. 2008;69:1 15) © 2008 Excerpta Medica Inc. 
Kwy WORDS: hydrochlorothiazide, t lmisartan, olmesartan, hypertension. 
INTRODUCTION 
Guidelines 1,2 for the treatment of hypertension i dicate a blood pressure (BP) goal of 
< 140/90 mm Hg in the general population with uncomplicated hypertension. Lower 
goals (130/80 mm Hg) are recommended for high-risk patients, such as those with 
concomitant renal disease, diabetes mellitus, or evidence of other target organ damage. 
These recommendations are supported by evidence accumulated from long-term trials 
suggesting that lower BP values are associated with better outcomes in a broad range 
of patients) ,4Several studies 5 8 have also found that >50% of patients with hypertension 
need >2 antihypertensive drugs to achieve their BP goals, regardless of the medication 
chosen as initial therapy. The advantages of combination therapy include greater BP 
reduction and response rates when compared with monotherapy. These are probably 
related to the simultaneous effect on several regulatory systems involved in abnormally 
elevated BP and to fewer adverse vents (AEs), with consequent better tolerability and 
improved treatment compliance. 9,1° 
Due to the large number of antihypertensive agents, the number of potential combi- 
nations is large. However, arational choice has to be based on the characteristics of each 
agent and their complementary mechanisms of action. 9'1° A logical combination might 
consist of a thiazide diuretic such as hydrochlorothiazide (HCTZ) and an angiotensin- 
receptor blocker (ARB). 11 13 The salt depletion induced by the diuretic stimulates 
the release of renin from juxtaglomerular cells. This reactive hyperreninemia makes 
BP maintenance dependent on angiotensin II, thereby blunting the antihypertensive 
efficacy of the diuretic. The addition of an ARB makes it possible to counteract the 
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renin-angiotensin system activation elicited by the diuretic and, in this way, to enhance 
the BP-lowering effect of salt depletion, ll 13 Even very low doses of HCTZ (12.5 mg/d) 
have been found to boost the BP-lowering effect of an ARB. 14,15 Furthermore, such 
a combination provides advantages in terms of better tolerability, because ARBs are 
associated with preventing or attenuating some of the metabolic AEs of HCTZ, such as 
hypokalemia and hyperglycemia. 12,13,15 
Given the importance of these pharmacodynamic considerations in the clinical set- 
ting, the efficacy of the HCTZ/ARB combination eeds to be assessed specifically for 
the individual ARB, especially when low doses of diuretic are used, as is often the case. 
In fact, the different pharmacokinetic properties of the various ARBs might produce 
different interactions with HCTZ, with possible consequences for clinical efficacy. 16 
The aim of this study was to evaluate the antihypertensive effect measured using 
ambulatory BP monitoring (ABPM) of the addition of HCTZ 12.5 mg* to monotherapy 
with telmisartan 80 mg* compared with the addition of the same dose of diuretic to 
monotherapy with olmesartan 20 mg~ in adults with moderate hypertension not adequate- 
ly controlled by monotherapy. 
PAT IENTS AND METHODS 
This prospective, randomized, open-label, blinded end point evaluation (PROBE), 17 
parallel-arm study was conducted from January 2006 to January 2007 at the Centro per 
l'Ipertensione  la Fisiopatologia Cardiovascolare, University of Pavia, Pavia, Italy. 
Consecutive outpatients of both sexes aged 39 to 75 years were considered eligible for 
enrollment if they had a sitting diastolic BP (DBP) >-99 mm Hg and <110 mm Hg at 
the end of an initial 2-week washout period. The patients with a sitting DBP >110 mm Hg 
or sitting systolic BP (SBP) >200 mm Hg at the end of the washout period were exclud- 
ed from the study, as were those with secondary or malignant hypertension, type 1 or 
type 2 diabetes mellitus, myocardial infarction or cerebrovascular accident within the 
preceding 6 months, heart failure, clinically significant valvular heart disease or ar- 
rhythmias, renal or hepatic insufficiency, pregnancy, or known hypersensitivity o the 
drugs used in the study. 
The study protocol was approved by the ethics committee of the University of Pavia and 
written informed consent was obtained from all patients prior to inclusion in the study. 
According to the study design, after a 2-week washout period during which any 
previous antihypertensive tr atment was discontinued, eligible patients were random- 
ized to olmesartan 20-mg tablets QD or telmisartan 80-mg tablets QD. In Italy, these 
are the doses recommended for initiating antihypertensive tr atment. Randomization 
was performed using a computer-generated random number sequence obtained from an 
investigator who was not involved in the patient recruitment. After 8 weeks of mono- 
therapy, patients whose BP was not adequately controlled (DBP >-90 mm Hg) were 
treated with the combination of olmesartan 20 mg and HCTZ 12.5 mg or telmisartan 
*Trademark: Esidrex ® (Novartis Pharmaceuticals, Basel, Switzerland). 
* Trademark: Micardis ® (Boehringer Ingelheim GmbH, Ingelheim, Germany). 
¢ Trademark: Olpress ® (Malesci, Firenze, Italy). 
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80 mg and HCTZ 12.5 mg, both administered QD in the morning for an additional 
8 weeks. At the end of each period (washout [baseline], monotherapy, combination 
therapy), BP was measured in the clinic and by noninvasive ABPM. Clinic BP was 
obtained in the sitting position by the same investigator using a standard mercury 
sphygmomanometer 24 hours after drug administration. Three measurements taken at 
2-minute intervals after the patient had been seated for 10 minutes were averaged and 
used as the clinic BP reference value. Heart rate (HR) was measured by palpating the 
radial artery after each BP measurement. 
ABPM was performed uring each 24-hour period using a clinically validated 18 
device (Spacelabs 90207, Spacelabs Healthcare, Tssaquah, Washington) programmed 
to measure BP every 15 minutes. Each recording started in the morning immediately 
after clinic BP assessment and drug administration. Patients were instructed to remain 
motionless each time a reading was taken. The analysis of 24-hour BP recordings was 
preceded by removal of artifacts according to previously described editing criteria. 19 
Recordings were considered valid when no more than 2 nonconsecutive hours were miss- 
ing over the 24-hour period. For each patient, the recordings were analyzed to obtain 
the following data relating to SBP, DBP, and HR: 24-hour mean values, daytime values 
(7 AMl l  PM), nighttime values i l l  PM 7 AM), and hourly mean values. 
The trough/peak (T/P) ratio, computed after selection of peak and trough changes, 
was also determined for each patient. 2° Peak changes were calculated by selecting the 
hour with the maximal reduction in BP between hours 2 and 8 after drug administra- 
tion and by averaging this change with the immediately adjacent hour in which the 
reduction was most evident. Trough BP changes were calculated by averaging the last 
2 hours of the recordings. 2°Based on the assumption that patients with hypertension 
are likely to receive the greatest benefit from treatment when the antihypertensive 
eflects do not vary greatly during the day, the US Food and Drug Administration 
(FDA) guidelines indicate that the eftect of an antihypertensive drug at the end of 
the dose interval (trough) should be no less than half to two thirds of the peak eflect. 
Therefore, a T/P ratio of 50% to 66% is required for the efficacy of an antihyperten- 
sive agent o be considered satisfactory for its proposed osage interval. 21 
The smoothness index (ST) was also computed by dividing the average of the 24-hour 
BP changes after treatment by the corresponding SD. 22,23 The ST has been shown to 
more appropriately reflect whether treatment smoothly reduced BP throughout the 
24-hour period than the T/P ratio. 
At each visit, AEs that were spontaneously reported or elicited by indirect question- 
ing by investigators blinded to patients' treatment were recorded. Serious AEs were 
defined as those requiring hospitalization or requiring drug withdrawal. Treatment 
compliance was assessed by counting the tablets remaining at each visit. 
According to the PROBE design, 17 the study outcomes were evaluated by physicians 
who were unaware of the type of treatment administered to the patients. 
STAT IST ICAL  ANALYS IS  
It was determined that a sample size of 40 patients in each group would have 80% 
power to detect a difference of >2.5 mm Hg in the primary end point of the study, the 
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24-hour DBP at the end of the treatment, assuming that the common SD was 4 mm Hg 
using a 2-group t test with a 0.05 two-sided significance level. Assuming a 10% drop- 
out rate, a total of 88 patients was deemed necessary for inclusion in the study. 
All statistical analyses were conducted using SAS version 6.12 (SAS Institute, Inc., 
Cary, North Carolina). Analysis of variance was used for BP results. Differences in T/P 
ratios between treatments were evaluated by nonparametric tests (Wilcoxon signed-rank 
test, univariate), whereas the paired Student test was used to assess the differences in 
SI. P < 0.05 was considered statistically significant. Data are shown as mean (SD). 
RESULTS 
One hundred forty-five vatients, all of whom were white, were recruited for the study. After 
the initial washout period, 13 vatients did not meet the inclusion criteria and 6 refused to 
continue. Consequently, 126 vatients (69 men, 57 women; mean [SD] age, 60.2 [11.6] years) 
were randomized to receive olmesartan 20 mg (n 63) or telmisartan 80 mg (n 63) 
(Table I). A total of 101 patients completed the study: 17 patients (10 in the telmisartan 
group and 7 in the olmesartan group) were excluded because their clinic BP was normalized 
(< 140/90 mm Hg) by monotherapy; 5 vatients (3 in the olmesartan group and 2 in the 
telmisartan group) because > 10% of all ABPM readings or > 1 reading per hour were missing 
or incorrect; 2 vatients (1 in the olmesartan group and 1 in the telmisartan group) because 
of poor BP control; and 1 patient (olmesartan group) because of lack of cooperation. 
Table I. Demographic and clinical characteristics of adult patients with moderate hyper- 
tension randomized to receive olmesartan 20 mg QD or telmisartan 80 mg QD 
monotherapy for 8 weeks followed by the addition of hydrochlorothiazide (HCTZ) 
12.5  mg for 8 weeks (N = 126).*  
Olmesartan/ Telmisartan/ 
Variable HCTZ HCTZ 
Patients randomized 63 
Age, mean (SD), y 60.1 (10.9) 
Sex, no. (%) 
Male 34 (54.0) 
Female 29 (46.0) 
BMI, mean (SD), kg/m 2 25.6 (0.5) 
SBP, mean (SD), mm Hg 169.1 (12.1) 
DBP, mean (SD), mm Hg 104.1 (6.2) 
HR, mean (SD), beats/min 74.7 (6.4) 
Duration of hypertension, mean (SD), y 11.5 (5.9) 
Smoking habit, no. (%) 10 (15.9) 
Previous antihypertensive therapy, no. (%) 35 (56.4) 
63 
59.9 (11.5) 
35 (55.6) 
28 (44.4) 
25.4 (0.4) 
169.7 (11.9) 
103.7 (6.4) 
74.9 (6.9) 
12.1 (6.4) 
13 (20.6) 
33 (52.8) 
BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate. 
*No significant between-group differences were found. 
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The ABPM evaluation performed at the end of the monotherapy period found that 
both monotherapy treatments significantly (both, P < 0.001) reduced ambulatory SBP 
and DBP values compared with baseline. However, the mean decreases in 24-hour SBP 
and DBP were significantly greater with telmisartan than with olmesartan (SBP/DBP: 
15.9 [8.8]/10.3 [5.1] mm Hg vs 13.6 [8.6]/8.7 [4.9] mm Hg, respectively; P < 0.05); 
decreases in nighttime SBP and DBP were also significantly greater with telmisartan 
(SBP/DBP: 15.6 [8.2]/10.7 [5.3] mm Hg vs 12.2 [7.5]/8.1 [4.9] mm Hg; P < 0.05). 
At the end of monotherapy, 52patients in the olmesartan group and 49 in the telmisartan 
group had their BP inadequately controlled by treatment and were administered additional 
HCTZ 12.5 mg QD. The results of the study refer to these 101 patients. Demographic and 
clinical characteristics of the initial cohort are reported in Table I. No statistically signifi- 
cant between-group differences were found in any of the baseline characteristics. 
Mean 24-hour, daytime, and nighttime ambulatory SBP and DBP values are reported 
in Table II. There was a further decrease in ambulatory BP at the end of the 8 weeks 
of combination therapy compared with the 8 weeks of monotherapy. Both treatment 
combinations significantly reduced both SBP and DBP from baseline to study end (all, 
P < 0.001). However, in the telmisartan/HCTZ-treated patients, the mean (SD) reduc- 
tions from baseline (SBP/DBP: 21.5 [10.1]/14.6 [5.2] mm Hg for 24 hours, 21.8 [10.2]/ 
14.9 [5.2] mm Hg for daytime, and 20.4 [10.3]/13.7 [5.9] mm Hg for nighttime) were 
all significantly greater than in the olmesartan/HCTZ-treated patients (18.8 [9.8]/ 
12.3 [4.9] mm Hg for 24 hours, 19.3 [9.8]/12.8 [4.9] mm Hg for daytime, and 17.4 [10.2]/ 
10.6 [5.5] mm Hg for nighttime) (all, P < 0.05) (Figure 1). 
When considering the difference in ABPM between the end of monotherapy and the 
end of combination therapy, the mean decreases in 24-hour, daytime, and nighttime 
SBP and DBP values obtained with the addition of HCTZ 12.5 mg to telmisartan 
monotherapy (5.0/3.4, 5.9/3.8, and 4.7/4.2 mm Hg, respectively) were significantly 
greater than those obtained with the addition of HCTZ 12.5 mg to olmesartan mono- 
therapy (3.8/2.8 mm Hg, P < 0.02; 4.8/2.9 mm Hg, P < 0.03; and 3.7/1.8 mm Hg, 
P < 0.02, respectively) (Figure 2). 
The hourly profile also found that the BP reduction obtained with the addition of 
HCTZ to telmisartan monotherapy was greater than that obtained with the addition of 
HCTZ to olmesartan monotherapy, particularly during the nighttime (Figure 3). 
The mean T/P ratio computed at the end of combination treatment was above the 
threshold of 0.5. No significant differences were found in the T/P ratios for SBP or DBP 
between the 2 groups (Table III). The mean Sis for SBP and DBP were also similar in 
the 2 combination treatment groups. 
Clinic BP data (Table IV) found a significant reduction in SBP and DBP with both 
olmesartan and telmisartan monotherapy compared with baseline. Again, the changes 
in both SBP and DBP compared with monotherapy were significantly greater when 
HCTZ 12.5 mg was added to telmisartan than to olmesartan (both, P < 0.05). 
Four patients in the olmesartan/HCTZ group complained of 3 AEs (nausea [2], 
headache [1], and fatigue [1]), while 3 patients in the telmisartan/HCTZ group com- 
plained of 2 AEs (fatigue [2] and nausea [1]). The rate of AEs (7% with olmesartan/ 
HCTZ and 6% with telmisartan/HCTZ) was not significantly different between the 
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Figure 1. Mean (SD) changes in ambulatory (A) systolic blood pressure (SBP) and (B) dia- 
stolic blood pressure (DBP) from baseline to study end in adults with moderate 
hypertension treated for 8 weeks with olmesartan 20 mg QD or telmisartan 
80 mg QD followed by the addition of hydrochlorothiazide (HCTZ) 12.5 mg for 
8 weeks (in both groups, all changes from baseline were statistically significant; 
P < 0.001). Olmesartan versus telmisartan: *P = 0.014; tp = 0.02; ~P = 0.011; 
§P = 0.016; lip _- 0.023; ITp = 0.004. 
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Figure 2. Mean (SD) changes in ambulatory (A) systolic blood pressure (SBP) and (B) dia- 
stolic blood pressure (DBP) induced by the addition of hydrochlorothiazide 
(HCTZ) 12.5 mg for 8 weeks to olmesartan or telmisartan monotherapy in 
adults with moderate hypertension not previously controlled on 8 weeks of 
monotherapy. Telmisartan versus olmesartan: *P = 0.002; tp = 0.009; ~P < 
0.001; §P < 0.007. 
CURRENT THERAPEUTIC RESEARCH 
N N 
I I 
mD 
C~ m) 
m~ 
O0 
o 
< 
l* 
l, 
I, 
i 
I 
I I I I 
~H u~u~ aQs V 
]~ 
I I 
(D 
o 
CO 
m 
1 
]* 
]* 
I 
I 
I 
i 
l, 
I 
i 
I 
I I I I I 
) LO 0 ~ 0 
I I I I I 
~H u~u~ aQ(] V 
] *  
0 ,m . 
ooE 
)) 
~.~°v 
A~ 
O 
"~v 
~Ag 
~ N .~:~ 
I.I. 
10 
R. FOGARIET AL. 
Table III. Mean (SD) trough/peak (T/P) ratio and smoothness index (SI) after 8 weeks 
of treatment with olmesartan 20 mg/hydrochlorothiazide (HCTZ) 12.5  mg QD 
and telmisartan 80 mg/HCTZ 12.5  mg QD. 
Variable T/P Ratio Sl 
SBP 
Olmesartan/HCTZ 0.56 (0.34) 2.54 (1.62) 
Telmisartan/HCTZ 0.59 (0.33) 2.96 (1.66) 
DBP 
Olmesartan/HCTZ 0.54 (0.28) 2.01 (1.08) 
Telmisartan/HCTZ 0.61 (0.31) 2.49 (1.01) 
SBP = systolic blood pressure; DBP = diastolic blood pressure. 
Table IV. Mean (SD) blood pressure (BP) and heart rate (HR) monitored in the clinic 
at baseline and after olmesartan 20 mg QD or telmisartan 80 mg QD mono- 
therapy (8 weeks) and olmesartan/hydrochlorothiazide (HCTZ) 12 .5  mg or 
te lmisartan/HCTZ 12.5  mg (16 weeks). 
Variable Baseline Monotherapy + HCTZ 
SBP, mm Hg 
Olmesartan 170.5 (12.6) 153.1 (6.4)* 145.3 (6.1)t 
Telmisartan 170.1 (12.1) 150.7 (6.1)* 140.1 (6.4)t~ 
DBP, mm Hg 
Olmesartan 104.1 (7.5) 94.2 (5.2)* 88.1 (5.1)t 
Telmisartan 103.7 (7.1) 93.3 (4.7)* 84.9 (4.9)t~ 
HR, beats/min 
Olmesartan 75.5 (7.4) 74.9 (6.9) 75.1 (6.8) 
Telmisartan 75.3 (7.2) 75.1 (6.7) 75.4 (6.6) 
SBP = systolic BP; DBP = diastolic BP. 
*P < 0.01 versus baseline. 
t p < 0.001 versus baseline. 
P < 0.05 versus olmesartan. 
2 combination therapies and was similar to the rate observed with the corresponding 
monotherapy (3 patients [5%] complained of nausea nd headache with olmesartan and 
2 [3%] complained of nausea nd fatigue with telmisartan). No serious AEs were con- 
sidered to be possibly or probably related to the trial medications. No patient withdrew 
from the study because of AEs and no serious AEs were reported. 
Based on counting the remaining tablets at each visit, 93% of the prescribed tablets 
were taken during telmisartan/HCTZ therapy and 92% during olmesartan/HCTZ thera- 
py, indicating ood overall treatment compliance. 
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DISCUSSION 
The results of the present study indicated that in moderately hypertensive patients com- 
bination therapy with both olmesartan 20 mg/HCTZ 12.5 mg and telmisartan 80 mg/ 
HCTZ 12.5 mg provided a clinically meaningful antihypertensive effect that was 
greater than that obtained with monotherapy. This is consistent with previous tudies 
that reported that the addition of HCTZ enhanced the efficacy of telmisartan 2427 and 
olmesartan. 16,28,29 However, the BP decrease resulting from the addition of HCTZ to 
telmisartan monotherapy was significantly greater than that observed when HCTZ was 
added to olmesartan monotherapy. This was true for SBP and DBP 24-hour mean val- 
ues, as well as for daytime and nighttime mean values. 
The clinic BP findings confirmed that the antihypertensive effect of telmisartan/ 
HCTZ combination therapy was superior to that of olmesartan/HCTZ at the end of the 
dosing interval after 8 weeks of combination treatment. These findings also confirmed 
that the add-on effect of HCTZ 12.5 mg administration ascompared with monotherapy 
was significantly greater in the telmisartan group than that in the olmesartan group. 
A limitation of this study was the lack of a control group that received either no 
therapy or HCTZ monotherapy, as we were not able to exclude the possibility that 
some of the BP reduction was temporal. However, our findings agree with those of a 
previous study 3° that found that HCTZ added to the ARB valsartan was more effec- 
tive than when added to olmesartan i  reducing BP values in moderately hypertensive 
patients inadequately controlled by monotherapy. In that study, plasma concentra- 
tions of HCTZ, which were determined after 8 weeks of combination therapy, were 
significantly greater in patients treated with valsartan/HCTZ than in those treated 
with olmesartan/HCTZ at each determination time (2, 4, and 24 hours after drug 
intake: 8.8 ng/mL, P < 0.05; 11.3 ng/mL, P < 0.05; 11.5 ng/mL, P < 0.05, respec- 
tively). This suggested that concomitant administration of olmesartan and HCTZ 
might decrease the bioavailability of HCTZ, at least at a dose of 12.5 mg. Although 
we did not determine HCTZ plasma concentrations, we hypothesize that the different 
pharmacokinetic profiles of telmisartan and olmesartan 31,32 might result in a differ- 
ent pharmacokinetic nteraction with low-dose HCTZ. Further data, however, are 
needed to confirm this hypothesis. 
Because acontinuous and graded relationship exists between BP values and cardiovascu- 
lar risk, lower BP values are associated with better outcomes in a broad range of patients) 3,34 
A number of studies have shown that even minor decreases in BP are associated with 
a reduction in hypertension-related morbidity and mortality, particularly in high-risk 
patients) 5 In the Heart Outcomes Prevention Evaluation study, 7a 3ram Hg SBP reduction 
was associated with a 22% decrease in cardiovascular events (P < 0.001). Similarly, in the 
Felodipine Event Reduction study, 36 an SBP/DBP reduction of 3.5/1.5 mm Hg was associ- 
ated with a 28% reduction in cardiovascular end points (P < 0.001), and in the Study 
on Cognition and Prognosis in the Elderlyy an SBP/DBP reduction of 3.2/1.6 mm Hg 
was associated with a significant decrease in the incidence of nonfatal stroke (P 0.04). 
Thus, the modestly greater decrease in SBP/DBP values we observed with telmisartan/ 
HCTZ combination therapy might be clinically relevant in terms of cardiovascular 
protection. 
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When assessing the duration of the hypotensive action over 24 hours, the T/P ratios 
for SBP and DBP obtained with both olmesartan/HCTZ and telmisartan/HCTZ given 
once daily fulfilled the FDA guidelines 38 (T/P ratio >50%) with no significant differ- 
ence in the ratio between the 2 regimens. The observed T/P ratios indicated that the 
antihypertensive effect of both combination therapies was sustained throughout he 
entire 24-hour period, making them suitable for once-daily administration. The SI, 
which provides information about the homogeneity of the antihypertensive effect, 22'23 
was similar in the 2 treatment groups. A greater T/P ratio and SI value reflects less 
variability in BP, which has been demonstrated to have an independent effect on organ 
damage and disease prognosis) 9 
Both combination therapies were well tolerated. The incidence of AEs was compa- 
rable in the olmesartan/HCTZ and the telmisartan/HCTZ groups (7% and 6%, respec- 
tively) and similar to the rates observed with monotherapy. The AEs were of mild or 
moderate intensity and transient in duration. This is in line with the tolerability profiles 
of ARBs when administered alone or in combination with HCTZ. 12 15 
CONCLUSION 
With the limitations due to the open design and the relatively short duration of treatment, 
findings of the present study indicated that in these adults with moderate hypertension 
not adequately controlled with monotherapy, the addition of HCTZ 12.5 mg to telmisar- 
tan 80 mg monotherapy was associated with greater ambulatory and clinic BP reductions 
than the addition of the same dose of HCTZ to olmesartan 20 mg monotherapy. 
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